We hear you! Your pharmacy workplace is stressed and stretched. You have rapidly growing concerns for patient safety. Still, you are there—every day—to care for your patients despite conditions that seem to be working against you.

WASHINGTON, DC – The American Pharmacists Association (APhA) today announced the selection of recipients of the APhA Academy of Pharmacy Practice & Management Awards and APhA Academy of Pharmaceutical Research & Science Awards as part of the 2022 APhA Awards and Honors Program.

This year has seen the approval of 2 new biosimilar drugs, including the first biosimilar to earn FDA’s “interchangeable” designation. Byooviz (ranibizumab-nuna) is biosimilar to Lucentis (ranibizumab), a drug for neovascular (wet) age-related macular degeneration (nAMD). Semglee (insulin glargine-yfgn), the first such drug to earn the “interchangeable” distinction, is biosimilar to Lantus (insulin glargine) for diabetes.

New data from CDC’s Autism and Developmental Disabilities Monitoring (ADDM) network show that 2.3% of children aged 8 years in 11 communities across the United States had an autism diagnosis in 2018.